Supplementary Figure Captions
between free USP7 and XL041 USP7 bound, and the deuterium incorporation plots for all 81 peptic peptides that were compared between USP7 free (red) and XL041bound (blue). On the x axis is the time in minutes and on the y-axis is the relative uptake (Da). The maximum y-axis value for each plot represents the theoretical maximum amount of D that can be incorporated into a peptide. Values represent the mean of two individual measurements; error bars, s.d. B. USP7 coverage map showing all the common peptic peptides that were compared between free USP7 and XL177A USP7 bound, and the deuterium incorporation plots for all 105 peptic peptides that were compared between USP7 free (red) and XL177A bound (blue). C. Chiclet representation of the HDX MS data. The peptides from panel A and B are represented from N to C terminus (top to bottom) at each time point (left to right). The deuterium level for each bound state was subtracted from that of the protein alone and colored according to the legend shown. The horizonal dotted lines are placed to help orient the readers to notice the regions of difference between the two states. Note that in the HDX MS data set the protein sequence numbering is different and Cys34 is actually Cys223. Figure S7 . Snapshot of the XL188-USP7 construct (red) and the XL177A-USP7 construct (orange) superimposed on each other after 150 ns of simulation time shows the benzyl moiety of XL177A in a similar confirmation to that of XL188. Figure S11: Cellular proliferation of panels of acute myeloid leukemia (AML); soft tissue sarcomas including two rhabdoid (G401, G402) and one uterine sarcoma (MES-SA); and multiple myeloma cell lines treated with XL177A (left) or XL177B (right). Red data points indicated TP53-WT cell lines, and black data points indicate TP53 mutants.
Figure S12: Top Panel: The indicated Ewing Sarcoma cell lines were treated with XL177B or GNE-6640 for 3 days, and viability was assessed by Cell Titer Glo. Red lines indicate p53-WT cells, and black lines indicate p53-mutant cells. Bottom Panel: TC32 cells stably expressing the indicated sgRNA was treated for 3 days with XL177B or GNE-6640 at the indicated doses, and viability was assessed by Cell Titer Glo. were treated with sgRNAs targeting the indicated genes, then allowed to grow for 17 days, with luminescence readings taken at the indicated timepoints. WT:KO ratio is equivalent to the FF:Renilla ratio. A. 10  20  30  40  50  60  70  80 90 100 110  120  130  140  150  160  170  180 190 200 10  20  30  40  50  60  70  80 90 100 
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A. Cell titerglo shows SB1_F_057 demonstrates no differential response based on TP53 status in Ewing sarcoma cell lines. B. Cell titerglo shows SB1_F_057 demonstrates no differential response in TC32 TP53 knock out cells. SB1_F_057 shows no differential response based on TP53 status 
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A. Cell titerglo shows SB1_F_057 demonstrates no differential response based on TP53 status in Ewing sarcoma cell lines. B. Cell titerglo shows SB1_F_057 demonstrates no differential response in TC32 TP53 knock out cells. SB1_F_057 shows no differential response based on TP53 status A549 RKO Figure S13 
Supplementary Synthetic Methods
Synthesis of XL177A, XL177B, XL112, XL041, and XL058 (see Figure S15 ):
Step 1 (Synthesis of S1): 7-nitroquinazolin-4(3H)-one (1.55g, 8.1mmol ) and tert-butyl-1-oxa-6azaspiro[2.5]octane-6-carboxylate (1.90g, 8.9mmol) were added into 20mL DMF. Cesium carbonate (7.82g, 24.0mmol) was added in one portion. The mixture was heated at 80°C overnight. The mixture was diluted with EtOAc, then washed with sat. NaCl. Combined organic layer was concentrated under reduced pressure. The crude product was purified by flash chromatography (EtOAc: hexanes: 50%-70%) to afford 2.42g S1 (75%). 1 Step 2 (Synthesis of S2): Compound S1(2.4g, 6.0mmol) was suspended in 20mL solvent (EtOH/AcOH=1:1). 4
eq. of Fe powder was added in portions. The mixture was stirred for 1 hour at 55°C. Then the reaction was cooled down to room temperature, and filtered through a pad of Celite. The filtrate was concentrated under reduced pressure to afford the crude product, which was then purified by flash chromatography (10%MeOH in EtOAc) to afford 2.1g product S2 (93%) 1 Step 3 (Synthesis of S3): Compound S2 (2.1g, 5.6mmol) was dissolved in anhydrous 10mL dichloromethane under N2 at 0°C. 3.0 eq. of Et3N was added. Then 3-bromopropionyl chloride (1.15g, 6.7mmol) was added dropwise. The mixture was stirred at 0°C for 1 hour, then quenched with MeOH, and concentrated under reduced pressure. The solid residue was directly used for the following step without further purification. The crude product from last step was dissolved in 10mL MeOH, then 3.0eq of Et3N was added. Into the stirred mixture was added 1-methylpiperazine (0.67g, 6.7mmol) dropwise. After the addition completed, the mixture was stirred for 1 hour at 50°C. Then the reaction mixture was cooled down to room temperature and concentrated under reduced pressure, then directly subjected to HPLC purification (MeOH/H2O with 4‰ TFA) to afford 2.1g product S3
(73% in two steps) 1 Step 4 (Synthesis of S4 (R 1 =(S)-Bn, R 2 =Cl)): S3 (0.53g, 1.0mmol) was dissolved in 3mL DCM, then 5mL 4M
HCl in 1,4-dioxane was added in portions. The solution was stirred for 1 hour at room temperature. Then the mixture was concentrated under reduced pressure, and left on high vacuum overnight to remove residual acid.
Then the product (0.11g, 0.25mmol) was dissolved in 3mL DMF, and basified by adding 10 eq of Et3N.
Sequentially, (S)-2-benzyl-5-((tert-butoxycarbonyl)amino)pentanoic acid (0.11g, 0.35mmol) Step 5 (Synthesis of XL177A): S4 (0.18g, 0.25mmol) was dissolved in 4M HCl in 1,4-dioxane, and stirred for 1h at room temperature. Then the mixture was concentrated under reduced pressure, and left on high vacuum overnight to remove residual solvent. Then the product (0.16g, 0.25mmol) was dissolved in 5mL DCM with 10 eq. of Et3N. Into the solution were added 9-chloro-5,6,7,8-tetrahydroacridine-3-carboxylic acid (0.10g, 0.4mmol) and T3P (50% in EtOAc) (0.42g, 1.3mmol). The solution was stirred at room temperature under nitrogen overnight. Then the mixture was concentrated under reduced pressure, and purified sequentially by flash chromatography (MeOH in EtOAc: 0%-70%) and HPLC (MeOH/H2O with 4‰ TFA) to afford 98mg XL177A (46%). N-(4-benzyl-5-(4-hydroxy-4-((7-(3-(4-methylpiperazin-1-yl) propanamido)-4-oxoquinazolin-3(4H)yl)methyl)piperidin-1-yl)-5-oxopentyl)-9-chloro-5,6,7,8-tetrahydroacridine-3-carboxamide. 1 149.32/149.27(conformer), 148.95, 145.59/145.56(conformer), 144.24, 139.97, 139.81/139.75(conformer), 135.19/135.17(conformer), 130.07/130.02(conformer), 128.93/128.79(conformer), 128.12/128.00(conformer), 127.43/127.37(conformer), 127.26/127.20(conformer), 125.99/125.94(conformer), 125.78, 125.37/125.32(conformer), 123.39, 118.25/118.20(conformer) 116.56/116.45(conformer), 114.67, 69.16/69.08(conformer), 54.62, 53.53/53.33(conformer), 53.44, 52.20, 45.54, 41.47/41.24(conformer), 40.90/40.68(conformer), 38.65, 37.01/36.96(conformer), 35.22, 34.63, 34.47, 34.26, 33.96, 33.56, 30.46, 29.66, 28.98, 27.05, 26.76, 21.86. LCMS (ESI) XL177B was synthesized according to procedure A using (R)-2-benzyl-5-((tert-butoxycarbonyl)amino)pentanoic acid in step 4 and 9-chloro-5,6,7,8-tetrahydroacridine-3-carboxylic acid in step 5. N-(4-benzyl-5-(4-hydroxy-4-((7-(3-(4-methylpiperazin-1-yl)propanamido)-4-oxoquinazolin-3(4H)yl)methyl)piperidin-1-yl)-5-oxopentyl)-9-chloro-5,6,7,8-tetrahydroacridine-3- XL112 was synthesized according to procedure A using (rac)-2-benzyl-5-((tert-butoxycarbonyl)amino)pentanoic acid in step 4 and 9-chloro-5,6,7,8-tetrahydroacridine-3-carboxylic acid in step 5. (4-benzyl-5-(4-hydroxy-4-((7-(3-(4-methylpiperazin-1-yl)propanamido)-4-oxoquinazolin-3(4H)yl)methyl)piperidin-1-yl)-5-oxopentyl)-9-chloro-5,6,7,8-tetrahydroacridine-3 37.51/37.46(conformer), 35.73, 35.13, 34.97, 34.78, 34.47, 34.06, 30.97, 30.16, 29.48, 27.56, 27.26/27.23(conformer) XL058 was synthesized according to procedure A using (rac)-2-benzyl-5-((tert-butoxycarbonyl)amino)pentanoic acid in step 4 and 5,6,7,8-tetrahydroacridine-3-carboxylic acid in step 5. (4-benzyl-5-(4-hydroxy-4-((7-(3-(4-methylpiperazin-1-yl) 52.84, 46.20, 41.97/41.74(conformer), 41.40/41.17(conformer), 39.18, 37.46, 35.72, 35.13, 34.95, 34.79, 34.47, 33.46, 30.97, 30.17, 29.03, 27.31, 23.05, 22.75 .LCMS (ESI) m/z 827.61 [(M+H) + C48H59N8O5 + calcd for 827.46] XL041 was synthesized according to procedure A using 5-((tert-butoxycarbonyl)amino)pentanoic acid in step 4
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and 9-chloro-5,6,7,8-tetrahydroacridine-3-carboxylic acid in step 5. N-(5-(4-hydroxy-4-((7-(3-(4-methylpiperazin-1-yl) 76, 170.28, 165.81, 160.83, 160.63, 149.94, 149.38, 145.93, 144.60, 140.44, 
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